Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
New York, NY–(Newsfile Corp. – December 14, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of common stocks Celsius Holdings Inc. (NASDAK:NASDAK:) between February 29, 2024 and September 4, 2024, inclusive of both dates (“Teaching Period”), important January 21, 2025 deadline for the chief prosecutor.
SO WHAT: If you purchased Celsius common stock during the class period, you may be entitled to reimbursement without paying any fees or out-of-pocket expenses through a contingency fee arrangement.
WHAT’S NEXT: To join the Celsius class action, go to https://rosenlegal.com/submit-form/?case_id=31677 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than January 21, 2025. The lead plaintiff is the representative party acting on behalf of other class members in the conduct of the litigation.
WHY ROSEN LAW: We encourage investors to select a qualified advisor with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any significant peer recognition. Many of these firms do not actually litigate securities class actions, but are merely brokers who refer clients or partners with the law firms that actually litigate the cases. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide, concentrating its practice on securities class actions and shareholder derivative litigation. The Rosen Law Firm achieved the largest securities settlement against a Chinese company at that time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (VA:) Services for the number of securities settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Lawrence Rosen was named a Titan of the Plaintiffs Bar Association by Law360. Lovedragon and Super Laviers have recognized many of the firm’s lawyers.
CASE DETAILS: According to the lawsuit, during the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Celsius significantly oversold PepsiCo (NASDAQ:), Inc. stock; (“Pepsi”) in high demand, and faced an impending sales cliff during which Pepsi would significantly reduce purchases of Celsius products; (2) as Pepsi reduced significant amounts of excess inventory, Celsius’ sales would decline significantly in future periods, harming Celsius’ financial performance and prospects; (3) Celsius’ rate of sales to Pepsi was unsustainable and created a false impression of Celsius’ financial performance and prospects; (4) as a result, Celsius’ business metrics and financial outlook were not as strong as indicated in defendants’ class statements; and (5) accordingly, Defendants’ statements regarding Celsius’ prospects and expected financial results were false and misleading at all relevant times. When the true details came to market, the lawsuit claims investors suffered damages.
To join the Celsius class action, go to https://rosenlegal.com/submit-form/?case_id=31677 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for class action information.
No class is certified. Until the class is certified, you are not represented by an attorney unless you retain one. You can choose a lawyer of your choice. You can also remain an absent member of the class and do nothing at this time. An investor’s ability to participate in a potential future recovery does not depend on whether it is the lead plaintiff.
Follow us for updates on LinkedIn: https://vvv.linkedin.com/company/the-rosen-lav-firm, on Twitter: https://tvitter.com/rosen_firm or on Facebook (NASDAK:) : https:/ /vvv.facebook.com/rosenlavfirm/.
Advertising Advertising. Previous results do not guarantee a similar outcome.
——————————
Contact information:
To view the original version of this press release, visit https://www.nevsfilecorp.com/release/233855
